Shots:

• The P-III FRESCO-2 study involves assessing of fruquintinib vs PBO in patients with m-CRC in ~130 sites across 10 countries
• The company has initiated the study in the US- EU- and Japan- while the first has been dosed in the US on Sept 03- 2020. The clinical data from P-III FRESCO study in Chinese patients and the global FRESCO-2 study would support NDA submission to the US FDA for patients with advanced m-CRC
•  EMA & PMDA has reviewed and endorsed the design of FRESCO-2 study. Fruquintinib is a highly selective and VEGFR 1/2/3 inhibitor and has received NMPA’s approval in Sept’2018 and commercially in late Nov’2018 by Eli Lilly under the name Elunate

­ Ref: Chi-Med | Image: Oncology News Australia